OBJECTIVE: To develop a prognostic model, based on clinical and pathological data, to estimate the probability of micrometastasis in the sentinel lymph node in patients with malignant melanoma. DESIGN: Retrospective analytical study. SETTING: University medical center. PATIENTS: Two hundred fifteen patients with American Joint Committee on Cancer stages I and II cutaneous malignant melanoma underwent sentinel lymph node biopsy. MEASUREMENTS: Presence of microscopic melanoma in the sentinel lymph node(s). Clinical attributes recorded included age, sex, and location of the primary melanoma. Pathological attributes recorded before lymph node evaluation included ulceration, microsatellites, angiolymphatic invasion, mitotic rate, tumor infiltrating lymphocytes, and regression. RESULTS: Forty-six patients (21.4%) overall had a positive sentinel lymph node. Patients with tumor thickness ranging from 3.0 to 3.9 mm had the highest incidence (50%) of nodal involvement, followed by those with tumors 4.0 to 4.9 mm thick (41%). Patients with melanomas measuring greater than 4.9 mm thick and those between 1.0 and 2.9 mm had a similar rate of nodal involvement (16%-17%). Clinical characteristics had minimal correlation with nodal status in multivariate analysis. The total number of histological high-risk features was significantly correlated with sentinel lymph node involvement. Important pathological risk factors included ulceration, high mitotic rate, angiolymphatic invasion, and microsatellites. Patients with tumor thickness greater than 1.0 mm but lacking these features had a 14% risk of occult metastases. CONCLUSION: Among patients with clinically node-negative primary melanoma, the presence of 1 or more high-risk histological features significantly increases the incidence of microscopic nodal involvement and can be used to predict the likelihood of a positive sentinel lymph node biopsy.
OBJECTIVE: To develop a prognostic model, based on clinical and pathological data, to estimate the probability of micrometastasis in the sentinel lymph node in patients with malignant melanoma. DESIGN: Retrospective analytical study. SETTING: University medical center. PATIENTS: Two hundred fifteen patients with American Joint Committee on Cancer stages I and II cutaneous malignant melanoma underwent sentinel lymph node biopsy. MEASUREMENTS: Presence of microscopic melanoma in the sentinel lymph node(s). Clinical attributes recorded included age, sex, and location of the primary melanoma. Pathological attributes recorded before lymph node evaluation included ulceration, microsatellites, angiolymphatic invasion, mitotic rate, tumor infiltrating lymphocytes, and regression. RESULTS: Forty-six patients (21.4%) overall had a positive sentinel lymph node. Patients with tumor thickness ranging from 3.0 to 3.9 mm had the highest incidence (50%) of nodal involvement, followed by those with tumors 4.0 to 4.9 mm thick (41%). Patients with melanomas measuring greater than 4.9 mm thick and those between 1.0 and 2.9 mm had a similar rate of nodal involvement (16%-17%). Clinical characteristics had minimal correlation with nodal status in multivariate analysis. The total number of histological high-risk features was significantly correlated with sentinel lymph node involvement. Important pathological risk factors included ulceration, high mitotic rate, angiolymphatic invasion, and microsatellites. Patients with tumor thickness greater than 1.0 mm but lacking these features had a 14% risk of occult metastases. CONCLUSION: Among patients with clinically node-negative primary melanoma, the presence of 1 or more high-risk histological features significantly increases the incidence of microscopic nodal involvement and can be used to predict the likelihood of a positive sentinel lymph node biopsy.
Authors: Richard L White; Gregory D Ayers; Virginia H Stell; Shouluan Ding; Jeffrey E Gershenwald; Jonathan C Salo; Barbara A Pockaj; Richard Essner; Mark Faries; Kim James Charney; Eli Avisar; Axel Hauschild; Friederike Egberts; Bruce J Averbook; Carlos A Garberoglio; John T Vetto; Merrick I Ross; David Chu; Vijay Trisal; Harald Hoekstra; Eric Whitman; Harold J Wanebo; Daniel Debonis; Michael Vezeridis; Aaron Chevinsky; Mohammed Kashani-Sabet; Yu Shyr; Lynne Berry; Zhiguo Zhao; Seng-Jaw Soong; Stanley P L Leong Journal: Ann Surg Oncol Date: 2011-06-07 Impact factor: 5.344
Authors: Michael S Sabel; John D Rice; Kent A Griffith; Lori Lowe; Sandra L Wong; Alfred E Chang; Timothy M Johnson; Jeremy M G Taylor Journal: Ann Surg Oncol Date: 2011-08-06 Impact factor: 5.344
Authors: Stanley P L Leong; Mohammed Kashani-Sabet; Renee A Desmond; Robert P Kim; Dennis H Nguyen; Kensho Iwanaga; Patrick A Treseler; Robert E Allen; Eugene T Morita; Yuting Zhang; Richard W Sagebiel; Seng-Jaw Soong Journal: World J Surg Date: 2005-06 Impact factor: 3.352
Authors: Alexander Meves; Ekaterina Nikolova; Joel B Heim; Edwin J Squirewell; Mark A Cappel; Mark R Pittelkow; Clark C Otley; Nille Behrendt; Ditte M Saunte; Jorgen Lock-Andersen; Louis A Schenck; Amy L Weaver; Vera J Suman Journal: J Clin Oncol Date: 2015-07-06 Impact factor: 44.544
Authors: A Mitra; C Conway; C Walker; M Cook; B Powell; S Lobo; M Chan; M Kissin; G Layer; J Smallwood; C Ottensmeier; P Stanley; H Peach; H Chong; F Elliott; M M Iles; J Nsengimana; J H Barrett; D T Bishop; J A Newton-Bishop Journal: Br J Cancer Date: 2010-09-21 Impact factor: 7.640
Authors: Cristian A Angeramo; Francisco Laxague; Enrique D Armella; Julieta Rodríguez Catán; Félix A Vigovich; Norberto A Mezzadri; Juan M Fernandez Vila Journal: Indian J Surg Oncol Date: 2021-08-29